Clinical trials: Short-course Radiotherapy Plus Chemotherapy
Rectal Cancer
SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer
TASOX can be safely and efficaciously delivered after short course radiation, resulting in significant pathologic downstaging, allowing for an R0 pelvic resection, and providing local control in appropriately selected stage…
- Trial name
- SHORT (NCT04417699)
- Testing
- TAS 102, Oxaliplatin
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Providence Health & Services
Gastroesophageal Adenocarcinoma
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
This is a randomized phase II study examining nivolumab alone versus radiation therapy with nivolumab in subjects who did not have disease progression to initial therapy with the combination of FOLFOX and Nivolumab.
- Trial name
- NCT04021108
- Testing
- Nivolumab 240 MG
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Weill Medical College of Cornell University